SeekingAlpha · Aug 27, 2026
How Investors Can Participate In AI
The explosion in usage of ChatGPT and other generative AI tools has opened investorsâ eyes to their potential to boost profits and productivity throughout the economy.
NYSE · ISRG
Intuitive Surgical, Inc.
Healthcare · Medical - Instruments & Supplies
$372.60
Up+$5.53 (+1.51%)
Updated Aug 31, 2026, 9:31 AM
SID Score
4.9/10
Composite research score
Smart Money
48/100
Neutral
- Market cap
- 195.51B
- P/E ratio
- 71.05
- Dividend yield
- 0.00%
- 52-week range
- $328.57 – $603.88
- Volume
- 1.8M
- Avg. volume
- 2.26M
Price performance
ISRG price history
1M range · 20 trading sessions · Daily adjusted prices
ISRG closed at $372.60 after 20 trading sessions, down 0.75% for the selected period.
- Last close
- $372.60
- Period change
- -0.75%
- Period low
- $367.07
- Period high
- $401.27
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $368.00 | $373.395 | $366.735 | $372.60 | 1.8M |
| Aug 27, 2026 | $369.61 | $372.305 | $366.90 | $367.07 | 1.79M |
| Aug 26, 2026 | $368.49 | $372.372 | $366.73 | $370.42 | 1.67M |
| Aug 25, 2026 | $375.25 | $378.23 | $367.0701 | $371.84 | 1.77M |
| Aug 24, 2026 | $379.25 | $384.06 | $373.48 | $373.57 | 1.52M |
| Aug 21, 2026 | $375.125 | $382.04 | $367.24 | $378.81 | 2.01M |
| Aug 20, 2026 | $397.225 | $398.99 | $372.60 | $374.48 | 3.97M |
| Aug 19, 2026 | $394.55 | $405.34 | $394.00 | $397.72 | 2.13M |
| Aug 18, 2026 | $394.00 | $399.8745 | $390.84 | $391.18 | 2.38M |
| Aug 17, 2026 | $392.10 | $396.99 | $389.67 | $390.33 | 2.16M |
| Aug 14, 2026 | $401.02 | $402.46 | $394.06 | $394.51 | 1.99M |
| Aug 13, 2026 | $403.72 | $404.69 | $398.00 | $401.27 | 2.36M |
| Aug 12, 2026 | $403.81 | $404.98 | $397.17 | $401.27 | 3.14M |
| Aug 11, 2026 | $392.22 | $402.14 | $392.22 | $401.23 | 4.12M |
| Aug 10, 2026 | $379.24 | $393.63 | $378.00 | $393.38 | 3.22M |
| Aug 7, 2026 | $374.55 | $379.90 | $372.6325 | $378.81 | 2.47M |
| Aug 6, 2026 | $374.39 | $378.6399 | $371.68 | $373.71 | 2.59M |
| Aug 5, 2026 | $372.80 | $376.625 | $369.4801 | $375.20 | 3.29M |
| Aug 4, 2026 | $376.31 | $376.31 | $364.26 | $368.265 | 3.94M |
| Aug 3, 2026 | $361.755 | $375.85 | $360.98 | $375.41 | 3.5M |
Latest ISRG news
The latest Smart Investors Daily articles mentioning ISRG.
Stock researchCompany · Overview
ISRG research
Overview
Company profile and research snapshot.
Company profile
Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 10,000 da Vinci systems in hospitals worldwide, with more than 6,000 installations in the US and a growing number in emerging markets.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $618.00
- Implied upside
- —
- Analysts
- 23
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 12, 2026 | Oppenheimer | Outperform | — |
| Jul 30, 2026 | HSBC | Hold | — |
| Jul 17, 2026 | Mizuho | Neutral | — |
| Jul 17, 2026 | TD Cowen | Buy | — |
| Jul 17, 2026 | Wells Fargo | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 22, 2026
How Slowing US Bariatric Procedures and Capital Constraints Will Impact Intuitive Surgical (ISRG) Investors
In the past year, Intuitive Surgical has seen procedure growth in the US slow, particularly in bariatric surgeries influenced by rising GLP-1 use, even as its operating margin widened for three consecutive years and management raised its 2026 non-GAAP gross margin forecast while continuing to fund R&D. An interesting tension is emerging as hospital capital budget constraints and shifting procedure mix weigh on growth expectations, even while analysts remain optimistic and management...
Benzinga · Aug 21, 2026
$1000 Invested In Intuitive Surgical 20 Years Ago Would Be Worth This Much Today
Intuitive Surgical (NASDAQ:ISRG) has outperformed the market over the past 20 years by 10.53% on an annualized basis producing an average annual return of 19.77%. Currently, Intuitive Surgical has a market
Yahoo · Aug 21, 2026
Form 8.3
LONDON, August 21, 2026-- FORM 8.3
AI research layers
Interpretive context generated from the platform’s current data sources.
Intuitive Surgical Stock Performance
Intuitive Surgical shares closed at $372.60, reflecting a daily decline of approximately 0.85%, per SID market data. The stock currently trades below both its 50-day moving average of $384.21 and its 200-day moving average of $455.12, indicating sustained downward momentum across multiple timeframes. Over the trailing one-year period, ISRG has declined 34.6%, a notable underperformance for a large-cap healthcare name. The one-month return of positive 5.56% suggests a modest near-term recovery, though the three-month loss of 12.26% underscores continued intermediate-term weakness. The 14-day relative strength index stands at 35.4, approaching oversold territory below the conventional 30 threshold. According to Massive/Polygon data, average daily trading volume is approximately 2.26 million shares. ISRG carries a beta of 1.686, indicating substantially higher volatility relative to the broader market, which has amplified recent drawdowns. The company's market capitalization stands at approximately $195.5 billion.
Intuitive Surgical Valuation Analysis
Intuitive Surgical trades at a price-to-earnings ratio of 71.05, reflecting a significant premium relative to the broader healthcare sector, per SID market data. The company's PEG ratio stands at 13.30, suggesting that even when adjusting for expected earnings growth, the valuation remains elevated by conventional standards. ISRG's price-to-book ratio of 11.53, according to SEC filings, further illustrates the market's premium pricing of the company's intangible competitive advantages in robotic-assisted surgery. The company pays no dividend, consistent with its growth-oriented capital allocation strategy. Despite the stock's 34.6% decline over the past twelve months, these multiples remain well above sector medians, reflecting the market's recognition of Intuitive Surgical's dominant position in surgical robotics and its installed base economics. The current valuation implies that investors continue to price in durable long-term revenue growth and margin expansion from procedure volume increases across the da Vinci platform ecosystem.
Smart Money Activity for ISRG
Intuitive Surgical's composite smart money score stands at 48 out of 100, generating a neutral signal, per SID market data. The institutional component scores a perfect 25 out of 25, indicating robust and sustained institutional ownership and accumulation among major fund managers. In contrast, the insider trading component registers at just 2.1 out of 25, reflecting a pronounced imbalance in insider activity. According to SEC Form 4 filings, there have been 14 insider transactions over the past 90 days, comprising only 2 purchases against 12 sales. This selling pattern warrants monitoring, though insider sales at elevated valuation levels are common for high-multiple growth companies and may reflect pre-scheduled 10b5-1 plan activity rather than directional conviction. The dark pool activity score of 8.5 out of 25 suggests moderate off-exchange trading interest. Congressional trading activity scores 12 out of 25 based on 13F institutional filings and congressional disclosure data. The divergence between strong institutional conviction and persistent insider selling creates a mixed smart money profile for ISRG at current levels.
Intuitive Surgical Earnings Outlook
Intuitive Surgical has delivered a consistent pattern of earnings beats across the three most recently reported quarters, according to company earnings reports. In Q4, the company posted earnings per share of $2.53 versus the consensus estimate of $2.09, a positive surprise of $0.44. The Q3 period produced the largest beat, with actual EPS of $2.50 against an estimate of $1.92, representing a $0.58 upside surprise. Most recently reported Q2 results showed EPS of $2.80 compared to the $2.41 estimate, a $0.39 beat. The upcoming Q1 report is scheduled for July 21, with analyst estimates currently set at $2.41 per share. The three consecutive beats averaging approximately $0.47 per quarter above consensus suggest that analyst models may be systematically underestimating Intuitive Surgical's earnings power, potentially driven by stronger-than-expected procedure volumes or favorable instrument and accessory attachment rates across the installed base.
Wall Street Analyst Ratings for ISRG
Wall Street analyst sentiment on Intuitive Surgical remains broadly constructive with some recent divergence, per SID consensus data. In the most notable recent action, Oppenheimer upgraded ISRG to Outperform from Perform on August 12, signaling renewed bullish conviction. Conversely, HSBC downgraded the stock to Hold from Buy on July 30, reflecting a more cautious stance. Following the Q2 earnings report on July 17, several firms maintained existing ratings: TD Cowen reiterated its Buy rating, Wells Fargo maintained Overweight, and Mizuho held its Neutral stance, according to Wall Street analyst reports. The split between constructive and neutral ratings reflects the ongoing tension between Intuitive Surgical's strong operational execution, evidenced by consecutive earnings beats, and valuation concerns at a 71.05 trailing P/E multiple. The post-earnings maintenance of positive ratings by TD Cowen and Wells Fargo suggests that the $0.39 Q2 earnings beat reinforced confidence among bullish-leaning analysts in the company's growth trajectory.
